Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept.
Vitale A, Cabibbo G, Iavarone M, Viganò L, Pinato DJ, Ponziani FR, Lai Q, Casadei-Gardini A, Celsa C, Galati G, Gambato M, Crocetti L, Renzulli M, Giannini EG, Farinati F, Trevisani F, Cillo U; HCC Special Interest Group of the Italian Association for the Study of the Liver. Vitale A, et al. Lancet Oncol. 2023 Jul;24(7):e312-e322. doi: 10.1016/S1470-2045(23)00186-9. Lancet Oncol. 2023. PMID: 37414020 Review.
Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis.
Guarino M, Viganò L, Ponziani FR, Giannini EG, Lai Q, Morisco F; Special Interest Group on Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Guarino M, et al. Dig Liver Dis. 2018 Nov;50(11):1105-1114. doi: 10.1016/j.dld.2018.08.001. Epub 2018 Aug 11. Dig Liver Dis. 2018. PMID: 30170908 Free article. Review.
Although studies suggest decreased incident hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAAs) for hepatitis C virus (HCV) infection, data are conflicting regarding risk and aggressiveness of recurrence in patients who have a history of tre …
Although studies suggest decreased incident hepatocellular carcinoma (HCC) after treatment with direct-acting antivirals (DAAs) for h …
Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M, Sessa A, Cossiga V, Morando F, Caporaso N, Morisco F; Special Interest Group on “Hepatocellular carcinoma and new anti-HCV therapies” of the Italian Association for the Study of the Liver. Guarino M, et al. World J Gastroenterol. 2018 Jun 28;24(24):2582-2595. doi: 10.3748/wjg.v24.i24.2582. World J Gastroenterol. 2018. PMID: 29962815 Free PMC article. Review.
Robust scientific evidence supports a beneficial role of SVR after interferon therapy in the progression of cirrhosis, resulting in a decreased incidence of hepatocellular carcinoma (HCC). However, a debate on the impact of DAAs on the development of HCC is ongoing. …
Robust scientific evidence supports a beneficial role of SVR after interferon therapy in the progression of cirrhosis, resulting in a decrea …
Clinical impact of sexual dimorphism in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Burra P, Bizzaro D, Gonta A, Shalaby S, Gambato M, Morelli MC, Trapani S, Floreani A, Marra F, Brunetto MR, Taliani G, Villa E; Special Interest Group Gender in Hepatology of the Italian Association for the Study of the Liver (AISF). Burra P, et al. Liver Int. 2021 Aug;41(8):1713-1733. doi: 10.1111/liv.14943. Epub 2021 Jun 8. Liver Int. 2021. PMID: 33982400 Review.
Effect of direct-acting antivirals on future occurrence of hepatocellular carcinoma in compensated cirrhotic patients.
Cucchetti A, D'Amico G, Trevisani F, Morelli MC, Vitale A, Pinna AD, Cescon M; from the Special Interest Group on Hepatocellular carcinoma and new anti HCV therapies of the Italian Association for the Study of the Liver (AISF). Cucchetti A, et al. Dig Liver Dis. 2018 Feb;50(2):156-162. doi: 10.1016/j.dld.2017.10.004. Epub 2017 Oct 18. Dig Liver Dis. 2018. PMID: 29102521
METHODS: A Markov model was built on clinical data of 494 cirrhotic patients and available literature to estimate probabilities of "death before HCC" and of "HCC occurrence" without and with DAA. RESULTS: In comparison to untreated patients, DAA therapy reduced the …
METHODS: A Markov model was built on clinical data of 494 cirrhotic patients and available literature to estimate probabilities of "death be …